Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Wildtype”

113 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 113 results

Testing effectiveness (Phase 2)Ended earlyNCT01351038
What this trial is testing

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Who this might be right for
KRAS Wild TypeResectable Type II Gastric Adenocarcinoma
Arbeitsgemeinschaft medikamentoese Tumortherapie 43
Testing effectiveness (Phase 2)Ended earlyNCT01522612
What this trial is testing

Colorectal Cancer (CRC) Cetuximab Elderly Frail

Who this might be right for
Colorectal Cancer Metastatic
European Organisation for Research and Treatment of Cancer - EORTC 5
Not applicableEnded earlyNCT01074333
What this trial is testing

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Who this might be right for
Colorectal Neoplasm
Merck KGaA, Darmstadt, Germany 146
Not applicableStudy completedNCT01082315
What this trial is testing

A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment

Who this might be right for
Colorectal Neoplasms
Merck KGaA, Darmstadt, Germany 730
Testing effectiveness (Phase 2)Ended earlyNCT01504477
What this trial is testing

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer
Georgetown University 6
Large-scale testing (Phase 3)Study completedNCT01412957
What this trial is testing

Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Amgen 377
Testing effectiveness (Phase 2)Study completedNCT01161316
What this trial is testing

Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours

Who this might be right for
Metastatic Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 194
Testing effectiveness (Phase 2)Study completedNCT03442569
What this trial is testing

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Who this might be right for
Colon Cancer
UNC Lineberger Comprehensive Cancer Center 56
Testing effectiveness (Phase 2)Study completedNCT01276379
What this trial is testing

Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab

Who this might be right for
Colorectal Cancer
Grupo Espanol Multidisciplinario del Cancer Digestivo 221
Testing effectiveness (Phase 2)Temporarily pausedNCT01088620
What this trial is testing

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
WiSP Wissenschaftlicher Service Pharma GmbH 134
Early research (Phase 1)Ended earlyNCT02199223
What this trial is testing

Regorafenib + Panitumumab for Colorectal Cancers

Who this might be right for
KRAS and NRAS Wild-type Colorectal Cancer
University of Utah 2
Testing effectiveness (Phase 2)Study completedNCT01229150
What this trial is testing

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Who this might be right for
Non Small Cell Lung Carcinoma
National Cancer Institute (NCI) 89
Early research (Phase 1)Study completedNCT01294826
What this trial is testing

Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Who this might be right for
Recurrent Colon CancerRecurrent Rectal CancerStage IV Colon Cancer+3 more
Swedish Medical Center 20
Testing effectiveness (Phase 2)UnknownNCT04466254
What this trial is testing

Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 75
Testing effectiveness (Phase 2)Study completedNCT00788957
What this trial is testing

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Who this might be right for
Colon CancerColorectal CancerGastrointestinal Cancer+2 more
NantBioScience, Inc. 177
Testing effectiveness (Phase 2)Study completedNCT02399943
What this trial is testing

A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer

Who this might be right for
Colorectal CancerKRAS WildtypeNRAS Wildtype+1 more
University Health Network, Toronto 14
Testing effectiveness (Phase 2)Study completedNCT00958386
What this trial is testing

Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)

Who this might be right for
Metastatic Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 61
Testing effectiveness (Phase 2)Study completedNCT03446157
What this trial is testing

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Who this might be right for
Cancer of the ColonColon CancerColon Neoplasms+2 more
UNC Lineberger Comprehensive Cancer Center 24
Testing effectiveness (Phase 2)Ended earlyNCT01523639
What this trial is testing

A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis

Who this might be right for
Colorectal CancerSteatohepatitis
Austrian Breast & Colorectal Cancer Study Group 8
Testing effectiveness (Phase 2)Study completedNCT00891930
What this trial is testing

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

Who this might be right for
Metastatic Colorectal Cancer
NantBioScience, Inc. 74
Load More Results